Leukemia Research
Volume 29, Issue 6 , Pages 661-664 , June 2005

Analysis of HFE and TFR2 gene mutations in patients with acute leukemia

  • Dino Veneri

      Affiliations

    • Dipartimento di Medicina Sperimentale e Clinica, Divisione di Ematologia, Università di Verona, 37134 Verona, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 045 8073610; fax: +39 045 8073612.
    • ,
  • Massimo Franchini

      Affiliations

    • Servizio di Immunoematologia e Trasfusionale, Azienda Ospedaliera di Verona, Verona, Italy
    • ,
  • Mauro Krampera

      Affiliations

    • Dipartimento di Medicina Sperimentale e Clinica, Divisione di Ematologia, Università di Verona, 37134 Verona, Italy
    • ,
  • Giovanna de Matteis

      Affiliations

    • Istituto di Analisi Chimico-Cliniche, Azienda Ospedaliera di Verona, Verona, Italy
    • ,
  • Pietro Solero

      Affiliations

    • Istituto di Analisi Chimico-Cliniche, Azienda Ospedaliera di Verona, Verona, Italy
    • ,
  • Giovanni Pizzolo

      Affiliations

    • Dipartimento di Medicina Sperimentale e Clinica, Divisione di Ematologia, Università di Verona, 37134 Verona, Italy

Received 6 December 2004 ,Accepted 17 December 2004.

References 

  1. Edwards CQ, Kushner JP. Screening for hemochromatosis. New Engl J Med. 1993;328:1616–1620
  2. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. New Engl J Med. 1999;341:718–774
  3. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJH. Global prevalence of putative haemochromatosis mutations. J Med Genet. 1999;34:275–278CQ
  4. Hannuksela J, Savolainen ER, Koistinen P, Parkkila S. Prevalence of HFE genotypes, C282Y and H63D in patients with hematologic disorders. Haematologica. 2002;87:131–135
  5. Good MF, Powell LW, Halliday JW. Iron status and cellular immune competence. Blood Rev. 1988;2:43–49
  6. Porto G, Cardoso PG, Gordeuk V, Cruz E, Fraga J, Areias J, et al. Clinical and genetic heterogeneity in hereditary hemochromatosis: association between lymphocyte counts and expression of iron overload. Eur J Haematol. 2001;67:110–118
  7. Nelson RL, Davis FG, Persky V, Becker E. Risk of neoplastic and other diseases among people with heterozygosity for hereditary hemochromatosis. Cancer. 1995;76:875–879
  8. Dorak MT, Burnett AK, Worwood M. Hemochromatosis gene in leukemia and lymphoma. Leuk Lymphoma. 2002;43:467–477
  9. Parkkila S, Niemela O, Savolainen ER, Koistinen P. HFE mutations do not account for transfusional iron overload in patients with acute myeloid leukemia. Transfusion. 2001;41:828–831
  10. Dorak MT, Burnett AK, Worwod M, Sproul AM, Gibson BE. The C282Y mutation of HFE is another male-specific risk factor for childhood acute lymphoblastic leukemia. Blood. 1999;94:3957–3958
  11. Gimferrer E, Nomdedeu J, Gich I, Barcelò MJ, Baiget M. Prevalence of hemochromatosis related HFE gene mutations in patients with acute myeloid leukemia. Leuk Res. 1999;23:597–598
  12. Van Landeghem GF, Beckman LE, Wahlin A, Markevärn B, Beckman L. Interaction between haemochromatosis and transferrin receptor genes in multiple myeloma. Lancet. 1998;352:1285–1286
  13. Veneri D, Franchini M, Zanetti F, Krampera M, de Matteis G, Pizzolo G. Iron overload in acute myeloid leukemia is not related to HFE and TFR2 gene mutations. Haematologica. 2003;88:1069–1070
  14. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposal for the classification of the acute leukaemias: French–America–British (FAB) Co-operative Group. Br J Haematol. 1976;33:451–458
  15. Beutler E, Felitti V, Gelbhart T, Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med. 2000;133:329–337
  16. Beutler E, Felitti V, Gelbart T, Waalen J. Haematological effects of the C282Y HFE mutation in homozygous and heterozygous states among subjects of northern and southern European ancestry. Br J Haematol. 2003;120:887–893
  17. Rossi E, Olynk JK, Cullen DJ, Papadopoulos G, Bulsara M, Summerville L, et al. Compound heterozygous hemochromatosis genotype predicts increased iron and erythrocyte indices in women. Clin Chem. 2000;46:162–166
  18. Barton JC, Bertoli LF, Rothenberg BE. Peripheral blood erythrocyte parameters in hemochromatosis: evidence for increased erythrocyte hemoglobin content. J Lab Clin Med. 2000;135:96–104
  19. Geier D, Hebert T, Potti A. Risk of primary non-hepatocellular malignancies in hereditary hemochromatosis. Anticancer Res. 2002;22:3797–3799
  20. Dorak MT, Lawson T, Machulla HKG , Darke C, Mills KI, Burnett AK. Unravelling an HLA-DR association in childhood acute lymphoblastic leukemia. Blood. 1999;94:694–700
  21. Barton JC, Bertoli LF. Transfusion iron overload in adults with acute leukemia: manifestations and therapy. Am J Med Sci. 2000;319:73–78
  22. Lichtman SM, Attivissimo L, Goldman IS, Schuster MW, Buchbinder A. Secondary hemochromatosis as a long-term complication of the treatment of hematological malignancies. Am J Hematol. 1999;61:262–264
  23. Cassanelli S, Pignatti E, Montosi G, Garuti C, Mariano M, Campioli D, et al. Frequency and biochemical expression of C282Y/H63D hemochromatosis (HFE) gene mutations in the healthy adult population in Italy. J Hepatol. 2001;34:523–528
  24. Mura C, Raguenes O, Férec C. HFE mutations in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood. 1999;93:2502–2505

PII: S0145-2126(05)00019-6

doi: 10.1016/j.leukres.2005.01.001

Leukemia Research
Volume 29, Issue 6 , Pages 661-664 , June 2005

Article Tools